Back to search
FDAFDA · Food and drugs·Recall number D-1058-2017

Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15

Published August 16, 2017 · Recall initiated: August 2, 2017

Summary

FDA records drug Class III recall D-1058-2017, published August 16, 2017 and initiated August 2, 2017. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 2,880 cartons (30 unit dose blister pack per carton); Lot: Lot # 3138405A, Exp 8/2017. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Moisture Limits: out of specification test results for water content obtained during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Product distributed to OH, IL, PA, MI, VA and CT
Lot
Lot # 3138405A, Exp 8/2017
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15 recalled?

Yes. FDA published recall D-1058-2017 on August 16, 2017. Reported hazard: Failed Moisture Limits: out of specification test results for water content obtained during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter